Format
Sort by
Items per page

Send to

Choose Destination

Best matches for baloxavir:

Susceptibility of Influenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil. Takashita E et al. Front Microbiol. (2018)

Baloxavir: First Global Approval. Heo YA et al. Drugs. (2018)

Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. Hayden FG et al. N Engl J Med. (2018)

Search results

Items: 1 to 20 of 32

1.

Baloxavir marboxil susceptibility of influenza viruses from the Asia-Pacific, 2012-2018.

Koszalka P, Tilmanis D, Roe M, Vijaykrishna D, Hurt AC.

Antiviral Res. 2019 Feb 13;164:91-96. doi: 10.1016/j.antiviral.2019.02.007. [Epub ahead of print]

2.

Pharmaceutical Approval Update.

Kaufman MB.

P T. 2019 Jan;44(2):42-44.

3.

Designing influenza polymerase acidic endonuclease inhibitors via 'privileged scaffold' re-evolution/refining strategy.

Ju H, Zhan P, Liu X.

Future Med Chem. 2019 Feb 14. doi: 10.4155/fmc-2018-0489. [Epub ahead of print] No abstract available.

PMID:
30763130
4.

Influenza virus polymerase inhibitors in clinical development.

Hayden FG, Shindo N.

Curr Opin Infect Dis. 2019 Feb 4. doi: 10.1097/QCO.0000000000000532. [Epub ahead of print]

PMID:
30724789
5.

Successes, failures, and future prospects of prodrugs and their clinical impact.

Najjar A, Karaman R.

Expert Opin Drug Discov. 2019 Mar;14(3):199-220. doi: 10.1080/17460441.2019.1567487. Epub 2019 Feb 4.

PMID:
30714428
6.

Promotion of Japan's participation in global clinical trials.

Kondo H, Shimada Y, Ozawa T.

Drug Discov Today. 2019 Jan 30. pii: S1359-6446(18)30508-7. doi: 10.1016/j.drudis.2019.01.016. [Epub ahead of print]

PMID:
30710642
7.

Baloxavir marboxil in Japanese patients with seasonal influenza: Dose response and virus type/subtype outcomes from a randomized phase 2 study.

Watanabe A, Ishida T, Hirotsu N, Kawaguchi K, Ishibashi T, Shishido T, Sato C, Portsmouth S, Tsuchiya K, Uehara T.

Antiviral Res. 2019 Mar;163:75-81. doi: 10.1016/j.antiviral.2019.01.012. Epub 2019 Jan 23.

PMID:
30684563
8.

Expanded table: Antiviral drugs for treatment and prophylaxis of seasonal influenza 2018-2019.

[No authors listed]

Med Lett Drugs Ther. 2019 Jan 14;61(1563):e11-e12. No abstract available.

PMID:
30681664
9.

Antiviral drugs for treatment and prophylaxis of seasonal influenza.

[No authors listed]

Med Lett Drugs Ther. 2019 Jan 14;61(1563):1-4. No abstract available.

PMID:
30681660
10.

[Baloxavir marboxil: a potent cap-dependent endonuclease inhibitor of influenza viruses].

Reina J, Reina N.

Rev Esp Quimioter. 2019 Feb;32(1):1-5. Epub 2019 Jan 23. Review. Spanish.

11.
12.

Baloxavir Marboxil: The First Cap-Dependent Endonuclease Inhibitor for the Treatment of Influenza.

Yang T.

Ann Pharmacother. 2019 Jan 23:1060028019826565. doi: 10.1177/1060028019826565. [Epub ahead of print]

PMID:
30674196
13.

Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons.

Gubareva LV, Mishin VP, Patel MC, Chesnokov A, Nguyen HT, De La Cruz J, Spencer S, Campbell AP, Sinner M, Reid H, Garten R, Katz JM, Fry AM, Barnes J, Wentworth DE.

Euro Surveill. 2019 Jan;24(3). doi: 10.2807/1560-7917.ES.2019.24.3.1800666.

14.

Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018.

Takashita E, Kawakami C, Morita H, Ogawa R, Fujisaki S, Shirakura M, Miura H, Nakamura K, Kishida N, Kuwahara T, Mitamura K, Abe T, Ichikawa M, Yamazaki M, Watanabe S, Odagiri T, On Behalf Of The Influenza Virus Surveillance Group Of Japan.

Euro Surveill. 2019 Jan;24(3). doi: 10.2807/1560-7917.ES.2019.24.3.1800698.

15.

Baloxavir marboxil (Xofluza) for treatment of influenza.

[No authors listed]

Med Lett Drugs Ther. 2018 Dec 3;60(1561):193-196. No abstract available.

PMID:
30653474
16.

Baloxavir.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

17.

Baloxavir marboxil, Fremanezumab-vfrm, Galcanezumab-gnlm, and Lofexidine hydrochloride.

Hussar DA, Moyer MR.

J Am Pharm Assoc (2003). 2019 Jan - Feb;59(1):141-144. doi: 10.1016/j.japh.2018.12.002. Epub 2018 Dec 21. No abstract available.

PMID:
30580925
18.

Susceptibility of Influenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil.

Takashita E, Morita H, Ogawa R, Nakamura K, Fujisaki S, Shirakura M, Kuwahara T, Kishida N, Watanabe S, Odagiri T.

Front Microbiol. 2018 Dec 6;9:3026. doi: 10.3389/fmicb.2018.03026. eCollection 2018.

19.

The prodrug approach in the era of drug design.

Najjar A, Karaman R.

Expert Opin Drug Deliv. 2018 Dec 18:1-5. doi: 10.1080/17425247.2019.1553954. [Epub ahead of print] No abstract available.

PMID:
30558447
20.

Population Pharmacokinetic and Exposure-Response Analyses of Baloxavir Marboxil in Adults and Adolescents Including Patients With Influenza.

Koshimichi H, Tsuda Y, Ishibashi T, Wajima T.

J Pharm Sci. 2018 Dec 15. pii: S0022-3549(18)30800-1. doi: 10.1016/j.xphs.2018.12.005. [Epub ahead of print]

Supplemental Content

Loading ...
Support Center